Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxypropyl betadex - Beren Therapeutics

Next Previous
X
Search
Drug Profile

Hydroxypropyl betadex - Beren Therapeutics

Alternative Names: BRN-002

Latest Information Update: 22 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beren Therapeutics
  • Class Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Ethers; Peripheral vasodilators; Urologics; Vascular disorder therapies
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atherosclerosis

Most Recent Events

  • 17 Nov 2022 Hydroxypropyl betadex receives Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for Homozygous Familial Hypercholesterolemia (HoFH) in UK
  • 15 Feb 2022 Beren Therapeutics plans a phase I trial for Atherosclerosis (In Volunteers) in New Zealand (IV) (ACTRN12622000198729)
  • 29 Oct 2021 Preclinical trials in Atherosclerosis in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top